179 related articles for article (PubMed ID: 16825030)
1. Novel dosage forms and regimens for sevelamer-based phosphate binders.
Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
[TBL] [Abstract][Full Text] [Related]
2. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
Fischer D; Cline K; Plone MA; Dillon M; Burke SK; Blair AT
Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
6. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
[TBL] [Abstract][Full Text] [Related]
10. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
12. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
13. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
[TBL] [Abstract][Full Text] [Related]
14. Calcium-based phosphate binders are appropriate in chronic renal failure.
Friedman EA
Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
[TBL] [Abstract][Full Text] [Related]
15. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
Nagano N; Miyata S; Obana S; Kobayashi N; Fukushima N; Burke SK; Wada M
Nephrol Dial Transplant; 2003 Oct; 18(10):2014-23. PubMed ID: 13679475
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do.
Pagé D; Knoll G
Adv Perit Dial; 2005; 21():185-7. PubMed ID: 16686315
[TBL] [Abstract][Full Text] [Related]
17. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
Fukushima N; Nagano N
Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
[TBL] [Abstract][Full Text] [Related]
18. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
20. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
